Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/EBIT ratio high or low?
The EV/EBIT ratio of 59.40x is in line with its estimated 1-year average of 63.01x, near the low end of its estimated 1-year range (54.62x–71.39x).
As of 2026-10-06T14:56:27.452Z.
Calculation as of: 2026-10-06T14:56:27.452Z.
Quote observation: 2026-10-06T14:54:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3daf5633c8ac25837d6b7f560b0674bc697d9f6607e17ed58c514225f564db96
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
59.40x
EV/EBIT RATIO AVG TTM
N/A
EV/EBIT RATIO AVG 3Y
N/A
EV/EBIT RATIO AVG 5Y
N/A
EV/EBIT RATIO AVG 10Y
N/A
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
22.04x
median of 166 covered companies
CURRENT VS SECTOR MEDIAN
+169.57%
vs the sector median at left
Market Cap
$1.21B
EV/EBIT Ratio
19.00x
TTM Avg
131.59x
3Y Avg
131.59x
5Y Avg
72.61x
Market Cap
$1.20B
EV/EBIT Ratio
190.14x
TTM Avg
76.16x
3Y Avg
60.11x
5Y Avg
60.11x
Market Cap
$1.16B
EV/EBIT Ratio
17.38x
TTM Avg
14.99x
3Y Avg
31.51x
5Y Avg
159.52x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.22B | 59.40x | N/A | N/A | N/A |
| Innovage Holding Corp. (INNV)vs › | $1.21B | 19.00x | 131.59x | 131.59x | 72.61x |
| Omada Health (OMDA)vs › | $1.22B | N/A | N/A | N/A | N/A |
| Kardigan, Inc. (KARD)vs › | $1.20B | N/A | N/A | N/A | N/A |
| MannKind Corporation (MNKD)vs › | $1.20B | 190.14x | 76.16x | 60.11x | 60.11x |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.23B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.17B | N/A | 9.18x | 9.18x | 16.99x |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 17.38x | 14.99x | 31.51x | 159.52x |
| OPKO Health, Inc. (OPK)vs › | $1.14B | N/A | 39.17x | 40.90x | 40.90x |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.14B | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-10-05 | 62.24x |
| 2026-10-02 | 61.63x |
| 2026-10-01 | 61.02x |
| 2026-09-30 | 63.77x |
| 2026-09-29 | 66.21x |
| 2026-09-28 | 67.12x |
| 2026-09-25 | 64.99x |
| 2026-09-24 | 64.38x |
| 2026-09-23 | 66.82x |
| 2026-09-22 | 67.73x |
| 2026-09-21 | 64.68x |
| 2026-09-18 | 65.29x |
| 2026-09-17 | 65.90x |
| 2026-09-16 | 63.46x |
| 2026-09-15 | 60.72x |
| 2026-09-14 | 61.94x |
| 2026-09-11 | 58.89x |
| 2026-09-10 | 59.50x |
| 2026-09-09 | 59.50x |
| 2026-09-08 | 60.41x |
| 2026-09-04 | 62.55x |
| 2026-09-03 | 62.55x |
| 2026-09-02 | 61.94x |
| 2026-09-01 | 66.21x |
| 2026-08-31 | 65.90x |
| 2026-08-28 | 66.21x |
| 2026-08-27 | 66.51x |
| 2026-08-26 | 71.39x |
| 2026-08-25 | 70.17x |
| 2026-08-24 | 67.12x |
| 2026-08-21 | 64.07x |
| 2026-08-20 | 61.33x |
| 2026-08-19 | 63.46x |
| 2026-08-18 | 61.02x |
| 2026-08-17 | 59.19x |
| 2026-08-14 | 58.89x |
| 2026-08-13 | 59.50x |
| 2026-08-12 | 59.80x |
| 2026-08-11 | 57.06x |
| 2026-08-10 | 54.62x |
| 2026-08-07 | 57.67x |
